InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
| IFRX Stock | USD 2.36 0.05 2.16% |
Slightly above 54% of InflaRx NV's investors are presently thinking to get in. The analysis of the overall investor sentiment regarding InflaRx NV suggests that some traders are interested. InflaRx NV's investing sentiment can be driven by a variety of factors including economic data, InflaRx NV's earnings reports, geopolitical events, and overall market trends.
InflaRx |
Achieved 30-patient recruitment milestone in Phase 3 vilobelimab trial in pyoderma gangrenosum to enable interim analysis, with guidance for trial size adaptation or futility expected by the end of 2Q 2025InflaRx pipeline highlighted at multiple medical congresses, including vilobelimab in COVID-19 and hidradenitis suppurativa and INF904Phase 2a trial for INF904 expected to initiate by year-end 2024, with first data readout expected in summer 2025European Committee for Medicinal Produc
Read at finance.yahoo.com
 |
InflaRx NV Fundamental Analysis
We analyze InflaRx NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of InflaRx NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of InflaRx NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
InflaRx NV is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
InflaRx NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with InflaRx NV stock to make a market-neutral strategy. Peer analysis of InflaRx NV could also be used in its relative valuation, which is a method of valuing InflaRx NV by comparing valuation metrics with similar companies.
Peers
InflaRx NV Related Equities
| INZY | Inozyme Pharma | 1.68 | ||||
| CCCC | C4 Therapeutics | 1.39 | ||||
| SLS | Sellas Life | 1.16 | ||||
| KZR | Kezar Life | 0.44 | ||||
| ELDN | Eledon Pharmaceuticals | 0.45 | ||||
| IKNA | Ikena Oncology | 0.60 | ||||
| PLX | Protalix Biotherapeutics | 1.64 | ||||
| FULC | Fulcrum Therapeutics | 1.74 | ||||
| EWTX | Edgewise Therapeutics | 1.88 | ||||
| ABOS | Acumen Pharmaceuticals | 1.93 | ||||
| KRON | Kronos Bio | 2.00 | ||||
| STOK | Stoke Therapeutics | 2.11 | ||||
| GBIO | Generation Bio | 2.52 | ||||
| PASG | Passage Bio | 2.56 | ||||
| ERAS | Erasca | 2.66 | ||||
| GLUE | Monte Rosa | 2.95 | ||||
| HOWL | Werewolf Therapeutics | 3.51 | ||||
| RVPH | Reviva Pharmaceuticals | 5.78 | ||||
| EYPT | Eyepoint Pharmaceuticals | 6.05 | ||||
| DSGN | Design Therapeutics | 8.79 |
Additional Tools for InflaRx Stock Analysis
When running InflaRx NV's price analysis, check to measure InflaRx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InflaRx NV is operating at the current time. Most of InflaRx NV's value examination focuses on studying past and present price action to predict the probability of InflaRx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InflaRx NV's price. Additionally, you may evaluate how the addition of InflaRx NV to your portfolios can decrease your overall portfolio volatility.